•  

Posts Tagged: cardiac surgery

MaRS Innovation forms third collaboration with Johnson & Johnson Innovation

MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest. The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615). This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech. Earlier this year, Johnson & Johnson Innovation and ...
June 11, 2015 in Centre for Addiction and Mental Health (CAMH), Industry Partners, Media Coverage, Member Institutions, News, Partnerships, TIAP Staff, University Health Network, University of Toronto
Read more

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

TORONTO, Jan. 12, 2015  — MaRS Innovation, the commercialization agent for Ontario's 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively. This announcement was covered in Lab Product News. "These three projects reflect the quality of innovation present in Toronto's research community for our industry partners, and Toronto's progress in addressing healthcare issues of international concern," ...
January 12, 2015 in Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Industry Partners, Licenseable Technologies, Member Institutions, News, Partnerships, Portfolio, University Health Network, University of Toronto
Read more

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development. This announcement was covered in Biotechnology Focus. The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced ...
October 20, 2014 in Funding or Fundraising-Announcements, Government Partners, Industry Partners, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies, Sunnybrook Health Sciences Centre, Vasomune Therapeutics Inc.
Read more